NEWS & RESOURCES

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold The Company's...

Alpheus Medical Treats First Patients in First-In-Human Clinical Trial for Novel High-Grade Glioma Brain Cancer Treatment Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas,...

FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer.
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)

Alpheus Medical Announces Formation of World-Class Scientific Advisory Board (SAB) to Support Development of Novel Treatment for Brain Cancer SAB to provide meaningful guidance as the company begins a first-in-human (FIH) clinical trial of their proprietary,...

Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced it has closed $16M in Series A financing.